-transparent.png){kind=logo}
To determine the significance of serum thyroglobulin (Tg) level in terms of presence or absence of thyroid cancer, we evaluated available serum Tg data on and off T4 therapy in 180 patients with differentiated thyroid cancer who have now been followed up to 18 yr. The presence of cancer was established by radioiodine scans, x-rays, and clinical examination. Thirty-two patients with detectable serum Tg autoantibodies were excluded from this analysis. Tg was measured by RIA with a sensitivity of 1 ng/mL. Patients who had all stages of cancer, but who had no evidence of active disease after treatment, were grouped according to operative and 131I ablative therapy. In patients with a partial thyroidectomy with or without ablation, the presence of Tg did not indicate the presence of cancer since levels were often above either a 5 ng/mL or a 10 ng/mL cutoff. The presence of residual normal thyroid tissue decreases the diagnostic value of serum Tg assay. In patients who underwent near total (NTT) or total thyroidectomy (TT) and 131I ablation, 3 of 55 (5.5%) patients had Tg greater than 5 ng/mL and 1 of 55 (1.8%) patients had Tg greater than 10 ng/mL during therapy, whereas off therapy 13 of 57 (22.8%) patients had Tg greater than 5 ng/mL and 6 of 57 (10.5%) patients had Tg levels greater than 10 ng/mL. In this group of patients, a Tg level less than 10 ng/mL during suppressive therapy indicated the absence of apparent tumor in 54 of 55 (98.2%) of patients. Whereas sensitivity of the assay was increased by withdrawal of hormone, "false positives" increased especially at lower (3-6 ng/mL) cut-off levels. No cut-off value properly categorized all patients. These data suggest, that even in patients who underwent 131I ablation and total thyroidectomy and were thought to be cured, small foci of thyroid tissue which are undetectable by standard 2 mCi 131I scans may exist and produce some Tg. However, these residual cells do not appear to cause an adverse prognosis in most patients. In patients with recurrent or continued disease, during T4 treatment, Tg levels ranged between 2-21,000 ng/mL and 5 of 11 patients had a Tg less than 5 ng/mL. Off treatment, Tg levels ranged between 6-10,700 ng/mL and 3 of 13 patients had a Tg less than 10 ng/mL. In 4 patients Tg levels were less than 10 ng/mL on treatment but greater than 10 ng/mL off therapy.(ABSTRACT TRUNCATED AT 400 WORDS)
M Ozata, and
S Suzuki, and
T Miyamoto, and
R T Liu, and
F Fierro-Renoy, and
L J DeGroot
October 2009,
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...,
M Ozata, and
S Suzuki, and
T Miyamoto, and
R T Liu, and
F Fierro-Renoy, and
L J DeGroot
August 1989,
Orvosi hetilap,
M Ozata, and
S Suzuki, and
T Miyamoto, and
R T Liu, and
F Fierro-Renoy, and
L J DeGroot
January 1984,
Cancer detection and prevention,
M Ozata, and
S Suzuki, and
T Miyamoto, and
R T Liu, and
F Fierro-Renoy, and
L J DeGroot
March 1998,
European journal of endocrinology,
M Ozata, and
S Suzuki, and
T Miyamoto, and
R T Liu, and
F Fierro-Renoy, and
L J DeGroot
August 2004,
Arquivos brasileiros de endocrinologia e metabologia,
M Ozata, and
S Suzuki, and
T Miyamoto, and
R T Liu, and
F Fierro-Renoy, and
L J DeGroot
September 1980,
Clinical endocrinology,
M Ozata, and
S Suzuki, and
T Miyamoto, and
R T Liu, and
F Fierro-Renoy, and
L J DeGroot
July 1997,
European journal of nuclear medicine,
M Ozata, and
S Suzuki, and
T Miyamoto, and
R T Liu, and
F Fierro-Renoy, and
L J DeGroot
January 1989,
Oncology,
M Ozata, and
S Suzuki, and
T Miyamoto, and
R T Liu, and
F Fierro-Renoy, and
L J DeGroot
May 1984,
Wiener klinische Wochenschrift,
M Ozata, and
S Suzuki, and
T Miyamoto, and
R T Liu, and
F Fierro-Renoy, and
L J DeGroot
November 1983,
Cancer,
